Wells Fargo Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $26

Wells Fargo analyst Eva Fortea Verdejo maintains Arcus Biosciences (NYSE:RCUS) with a Equal-Weight and raises the price target from $23 to $26.